Skip to main content
SpringerLink
Log in

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis

  • Regional Cancer Therapies
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Due to the increased adoption of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), patients with malignant peritoneal mesothelioma (MPM) have seen improved outcomes. We aimed to evaluate and synthesize the recent published literature.

Methods

The review was conducted according to the recommendation of the Meta-Analysis of Observational Studies in Epidemiology group with prespecified inclusion and exclusion criteria. The DEALE method was used to combine mortality rates, and imputation techniques were used to calculate standard errors. Meta-regression techniques were used to synthesize data. Publication bias was assessed using funnel plots.

Results

Of 6,528 citations collected, 20 articles reporting on 1,047 patients were included in the analysis. The median age was 51 years (interquartile range 49–55), with 59 % (54–67) female. The median peritoneal carcinomatosis index score was 19 (16–23). Complete cytoreduction (CC0, 1) was performed in 67 % (46–93 %) of patients. Pooled estimates of survival yielded a 1-, 3- and 5-year survival of 84, 59, and 42 %, respectively. Patients receiving early postoperative intraperitoneal chemotherapy [EPIC] (44 %) and those receiving cisplatin intraperitoneal chemotherapy alone (48 %) or in combination (44 %) had an improved 5-year survival.

Conclusions

While CRS + HIPEC has led to an improved survival for patients with MPM compared to historic data, heterogeneity of studies precludes generalizable inferences. EPIC chemotherapy and cisplatin chemoperfusion may infer survival benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. Med Gen Med. 2007; 9:32.

    PubMed Central  PubMed  Google Scholar 

  2. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007; 18:827–34.

    Article  CAS  PubMed  Google Scholar 

  3. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007; 18:985–90.

    Article  CAS  PubMed  Google Scholar 

  4. Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009; 99:109–13.

    Article  PubMed  Google Scholar 

  5. Janne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005; 7:40–6.

    Article  CAS  PubMed  Google Scholar 

  6. Simon GR, Verschraegen CF, Janne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008; 26:3567–72.

    Article  CAS  PubMed  Google Scholar 

  7. Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma: results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009; 64:211–8.

    Article  CAS  PubMed  Google Scholar 

  8. Le DT, Deavers M, Hunt K, Malpica A, Verschraegen CF. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Invest. 2003; 21:682–9.

    Article  CAS  PubMed  Google Scholar 

  9. Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2013; 21(4):1159–65.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Elias D, Bedard V, Bouzid T, et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007; 31:784–8.

    Article  PubMed  Google Scholar 

  11. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003; 12:605–21, xi.

  12. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283:2008–12.

    Article  CAS  PubMed  Google Scholar 

  13. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995; 221:29–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the “DEALE”). II: use in medical decision-making. Am J Med. 1982; 73:889–97.

    Article  CAS  PubMed  Google Scholar 

  15. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6:e1000097.

    Article  Google Scholar 

  16. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009; 27:6237–42.

    Article  PubMed  Google Scholar 

  17. Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013; 20:1093–100.

    Article  PubMed  Google Scholar 

  18. Schaub NP, Alimchandani M, Quezado M, et al. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol. 2013; 20:555–61.

    Article  PubMed  Google Scholar 

  19. Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol. 2007; 14:2790–7.

    Article  CAS  PubMed  Google Scholar 

  20. Baratti D, Vaira M, Kusamura S, et al. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Eur J Surg Oncol. 2010; 36:1047–53.

    Article  CAS  PubMed  Google Scholar 

  21. Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006; 13:405–12.

    Article  CAS  PubMed  Google Scholar 

  22. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001; 67:999–1003.

    CAS  PubMed  Google Scholar 

  23. Ma GY, Bartlett DL, Reed E, et al. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am. 1997; 3:174–9.

    CAS  PubMed  Google Scholar 

  24. Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000; 87:1587–93.

    Article  CAS  PubMed  Google Scholar 

  25. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992; 118:547–50.

    Article  CAS  PubMed  Google Scholar 

  26. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003; 21:4560–7.

    Article  CAS  PubMed  Google Scholar 

  27. Yano H, Moran BJ, Cecil TD, Murphy EM. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol. 2009; 35:980–5.

    Article  CAS  PubMed  Google Scholar 

  28. Yonemura Y, Ishibashi H, Canbay E, et al. Treatment results of diffuse malignant peritoneal mesothelioma. Gan To Kagaku Ryoho. 2012; 39:2416–9.

    PubMed  Google Scholar 

  29. Tudor EC, Chua TC, Liauw W, Morris DL. Risk factors and clinicopathological study of prognostic factors in the peritoneal mesothelioma. Am Surg. 2010; 76:400–5.

    PubMed  Google Scholar 

  30. Deraco M, De Simone M, Rossi CR, et al. An Italian multicentric phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma. J Exp Clin Cancer Res. 2003; 22:41–5.

    CAS  PubMed  Google Scholar 

  31. Macuks R, Ozdemir H, Dursun P, Ozen OI, Haberal N, Ayhan A. Malignant intraperitoneal mesothelioma-Baskent University experience. J Turk Ger Gynecol Assoc. 2011; 12:104–9.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010; 17:2720–7.

    Article  PubMed  Google Scholar 

  33. Chua TC, Yan TD, Deraco M, et al. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. Br J Surg. 2011;98:60-4.

    Article  CAS  PubMed  Google Scholar 

  34. Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol. 2011; 103:822–31.

    Article  PubMed  Google Scholar 

  35. Strasberg SM, Hall BL. Postoperative morbidity index: a quantitative measure of severity of postoperative complications. J Am Coll Surg. 2011; 213:616–26.

    Article  PubMed  Google Scholar 

  36. Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma: an update on treatment. Cancer Treat Rev. 2012; 38:605–12.

    Article  PubMed  Google Scholar 

  37. Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2011; 117:1855–63.

    Article  PubMed  Google Scholar 

  38. Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006; 13:229–37.

    Article  PubMed  Google Scholar 

  39. Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013; 178:645–51.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Hartz A, Bentler S, Charlton M, et al. Assessing observational studies of medical treatments. Emerg Themes Epidemiol. 2005; 2:8.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

DISCLOSURES

No relevant financial disclosures.

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA

    Joseph H. Helm MD, John T. Miura MD, Jason A. Glenn MD, Rebecca K. Marcus MD, Gregory Larrieux MD, Thejus T. Jayakrishnan MD, Amy E. Donahue MLIS, T. Clark Gamblin MD, MS, Kiran K. Turaga MD, MPH & Fabian M. Johnston MD, MHS

Authors
  1. Joseph H. Helm MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John T. Miura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jason A. Glenn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rebecca K. Marcus MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gregory Larrieux MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thejus T. Jayakrishnan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Amy E. Donahue MLIS
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T. Clark Gamblin MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kiran K. Turaga MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Fabian M. Johnston MD, MHS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabian M. Johnston MD, MHS.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Helm, J.H., Miura, J.T., Glenn, J.A. et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis. Ann Surg Oncol 22, 1686–1693 (2015). https://doi.org/10.1245/s10434-014-3978-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-3978-x

Keywords

Search

Navigation